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Background: Streptococcus pyogenes (group A streptococcus; GAS) is an etiological agent for pharyngitis, pyoderma,
and invasive infections in humans. Pharyngitis and pyoderma may lead to serious immune sequelae such as
rheumatic heart disease and post-streptococcal glomerulonephritis (PSGN). Streptococcal Inhibitor of Complement (SIC)
and its orthologue, distantly related to SIC (DRS), are virulence factors expressed by only four of more than 100 M types
of GAS. These four types (M1, M57, M12 and M55) are among the M types, which are associated with PSGN. In several
populations PSGN has been shown to be a risk factor for chronic kidney disease (CKD) and end-stage renal disease
(ESRD). Previous studies showed SIC or DRS antibody-prevalence was associated with PSGN, and seroprevalence of SIC
antibodies is significantly high among CKD and ESRD patients in Mumbai.
Methods: Streptococcal isolates recovered from GAS pyoderma cases were typed. Seropositivity for SIC and DRS
antibodies in subjects with pyoderma, PSGN pediatric cases, age matched healthy controls and non-GAS pyoderma
cases were determined.
Results: We confirm in this study an association between seroprevalence to SIC and DRS antibodies, and PSGN in
Mumbai population despite low point prevalence of M1, M12, M55 and M57. In addition we extended the study
to GAS-pyoderma and non-GAS pyoderma cases. To our surprise, we found a positive association between the
seroprevalence to SIC and DRS antibodies, and GAS-pyoderma owing to infection with diverse M types. The mechanism
of increased predisposition to pyoderma owing to infection by diverse GAS among SIC or DRS antibody-positive
population is not clear. Nonetheless, our findings could be explained by a phenomenon akin to antibody-dependent
enhancement (ADE).
Conclusions: This is the first report showing a small number of GAS M types conferring predisposition to pyoderma by
diverse types. Implications of this ADE-like phenomenon are discussed in the light of evolutionary advantage to GAS,
vaccine design and control of renal diseases.
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Streptococcus pyogenes (group A streptococcus; GAS), a
human-specific pathogen, is responsible for diverse dis-
eases such as pharyngitis, pyoderma, cellulitis, necrotis-
ing faciitis, toxic shock syndrome and life-threatening
immune sequelae including rheumatic heart disease and
post-streptococcal glomerulonephritis (PSGN) [1,2].
Pharyngitis and pyoderma caused by some GAS strains
(emm types) are associated with PSGN, of which emm1,
12, 55, 57 are among the major ones. These emm types
express a major secretory antigen called Streptococcal
Inhibitor of Complement (SIC; in emm1 and emm57)
or its orthologue called distantly related to SIC (DRS;
in emm12 and emm55) [3-5]. Although Sagar et al. [6]
reported that SIC was expressed by isolates of emm1-2
type which was claimed to be distinct from emm1 sub-
types, isolates of both emm1 and emm1-2 are clonally
related. Both SIC and DRS elicit high antibody re-
sponses during natural infections and the antibodies
are persistent [7,8].
Serological reactions to several GAS antigens have
been observed subsequent to PSGN [9]. In an earlier
community-based study seropositivity to DRS, but not
to SIC, was found to be associated with history of PSGN
among the Indigenous Australians [8]. Subsequently a
Swedish hospital-based study found an association be-
tween acute PSGN cases and IgM antibodies to SIC in
sera from pediatric cases [10]. The apparent differences
in the above results could be because of differences in
the distribution of emm types in these two geographical
regions, to the differences in study design or both. Al-
though the prognosis of PSGN is generally excellent,
many studies suggest that PSGN is a strong risk factor
for chronic kidney disease (CKD) and end-stage renal
disease (ESRD) [11-14]. Interestingly we recently showed
[15] that SIC antibody seroprevalence is higher in CKD
and ESRD patients than in control subjects in Mumbai,
a region endemic for streptococcal diseases. Further-
more we found that anti-SIC seropositivity in CKD
patients may result in poor prognosis, the disease pro-
gressing to ESRD. These findings warranted a hospital-
based investigation of association between SIC and DRS
antibody-prevalence and PSGN in Mumbai area.
We now show that acute PSGN pediatric patients have
high seroprevalence for SIC and DRS antibodies. We
also extended this study to pyoderma patients attending
outpatient wards of the same hospital. To our surprise
we found that significantly greater proportion of GAS
pyoderma patients are positive to SIC and DRS anti-
bodies than those with non-GAS pyoderma patients, or
age-matched healthy control subjects. Despite this
observation, SIC or DRS positive emm types were not
overly represented among the isolates from the GAS
pyoderma cases. This startling finding clearly highlightsincreased predisposition to GAS pyoderma in Mumbai
region among the subjects seropositive to SIC or DRS
antibodies due to past infection with emm types express-
ing these antigens. We attribute this to a phenomenon
akin to antibody-dependent enhancement (ADE) of skin
infection. However, only a limited number of GAS
strains seem to confer ADE of infection by diverse GAS
types. Such ADE may have a role in the evolution of
GAS as a highly successful human pathogen. We discuss
implications of our findings in relation to the manage-
ment of CKD patients and vaccine strategy.
Methods
Subjects, swabs and blood collection
Informed consent was obtained from all participants and
guardians. The study was conducted under ethics com-
mittee approval from Seth G.S. Medical College & KEM
Hospital (reference number, EC/GOVT-4/2010). All the
patients and control subjects are of similar demography.
All the subjects included were from low socio-economic
strata living in vicinity of KEM Hospital and the study
was conducted in 2 years between June 2011 and June
2013. They were therefore temporally and geographically
matched populations. The control 1 subjects were age-
matched to that of PSGN patients; they are paediatric
population. The control 2 subjects and the cases of non-
GAS pyoderma (caused by Staphylococcus) were age
matched to that of GAS pyoderma cases (mainly adult
population).
Swabs from 701 patients attending skin-outpatient de-
partment at KEM hospital were collected during 2 years
of the study period. GAS isolates were recovered from
150 subjects with primary GAS pyoderma diagnosed as
impetigo, superficial folliculitis, ecthyma and furuncles.
Multiple isolates were available from the same swab for
20 cases among the pyoderma cases. For further 17 cases
while mixed infections with GAS and Staphylococcus
were found in some skin sores, no multiple strains of
GAS was recovered from a patient.
Blood samples for sera were collected from a) the
above 150 GAS pyoderma subjects (mean age 25.1 ±
17.09 years; range 2–48 years) at the time of their visit
to the hospital’s outpatient department, and b) 25 chil-
dren with PSGN (mean age 7.12 ± 3.13 years; range 1–11
years) admitted to the pediatric ward of KEM hospital di-
agnosed as acute nephritic syndrome and having ASO
titres > 300 IU (see below).
Blood samples were also collected from 50 non-GAS
pyoderma cases (mean age 25 years; range 2–37 years)
and two age-matched control groups (control group 1
for PSGN [n = 25; mean age 6.6 years]; and control
group 2 for pyoderma [n = 50; mean age 25.8 years]).
Sera samples from patients and healthy individuals were
stored at −80°C until used.
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The isolates were characterized by emm typing accord-
ing to the protocol described at www.cdc.gov/ncidod/
biotech/strep/strepblast.htm.
Serology
Anti-streptolysin O (ASO) titers in sera were determined
according to Karmarkar et al. [16]. Both control groups
had no known history of streptococcal infections. ASO
titers were <300 IU for control groups. Non-GAS pyo-
derma are ASO negative.
Serum antibody titres for SIC and DRS were measured
by Enzyme-Linked Immunosorbent Assay (ELISA) as
described by Karmarkar et al. [15]. Briefly, high binding
flat bottomed immune plates (Himedia) were coated by
adding 100μl of recombinant his-thioredoxin-tagged
SIC, DRS or recombinant his-tagged thioredoxin (100
μg/ml; in carbonate buffer, pH 9.6) per well and incubat-
ing overnight at 4°C. After blocking with denatured ca-
sein hydrolysate (5% in PBS) for 2 hours, the bound
protein was allowed to react with a 1 in 300 dilution of
human serum for 1 hour in the same buffer containing
0.05% Tween-20 at room temperature. After washing 5
times with 0.05% Tween-20 in PBS, secondary anti-
human IgG antibody conjugated with peroxidase
(Sigma-Aldrich) was added and the reactions were
detected with 3,3′,5,5′-tetramethylbenzidine (Sigma-
Aldrich). The reaction was terminated with stopping so-
lution after 30 min incubation and optical density (OD)
was measured at 450 nm. Seropositivity or seronegativity
was determined by using cutoff values as described
below (see statistical analysis). Experimental controls
with no antigen, recombinant his-tagged thioredoxin, no
sera, and no secondary antibodies were included.
Competitive ELISA
Serum samples (1 in 300 dilution in PBS, pH 7.4) were
pre-incubated at 37°C with competitor antigens for 1
hour before adding to plates coated with SIC or DRS.
The competing antigens were: a) no antigen (control), b)
10 μg of SIC, DRS or both, c) 50 μg of SIC, DRS or both.
The rest of ELISA conditions were as described above.
Urinalysis
Urine was collected for all PSGN cases and the control
group 1. Proteinuria, protein-creatinine ratio, blood cells
in urine were determined as described earlier [17,18].
Statistical analysis
Cutoff values to assess whether or not a serum sample
should be regarded as positive for SIC or DRS antibody
were determined as before [15] and were obtained by
taking two standard deviations above the mean OD
values for control groups for SIC and DRS separately.Sera samples with OD values above the cutoff are scored
as positive. Statistical significance was calculated by un-
paired t-test.
Results
Heterogeneity of strains recovered from pyoderma cases
Of the 701 patients, GAS isolates were recovered from
150 pyoderma cases. Multiple isolates from the same
skin sore for each subject were analyzed for 20 pyo-
derma patients, and in an additional 17 pyoderma cases
isolates from multiple skin sores were emm typed. In all,
the isolates belonged to 57 emm types or sub-types over
the 2 year study period, and each type is represented by
1–5 isolates in a year (Table 1). Hence there was no
evidence for expansion or outbreak of a particular type
during this study. Of the 150 isolates only 7 (4.7%) were
emm1 and emm12 which express SIC and DRS respect-
ively (marked by # in Table 1); emm55 and emm57 were
not recovered. Despite high diversity, multiple GAS
isolates from patients (different colonies from the same
swab or different swabs; n = 37) were of the same type
for each patient. Taken together our results show it is
unlikely that SIC- or DRS-positive types per se are main
contributors to pyoderma in these subjects; instead
diverse emm types circulating in the community are re-
sponsible for skin infection.
Anti-SIC and anti-DRS seroprevalence
Sera from a) the 150 GAS pyoderma subjects, b) 25
children with PSGN, c) 50 non-GAS pyoderma cases,
d) two age-matched control groups; control 1 for PSGN
and control 2 for GAS pyoderma were analysed for
various parameters. Both the control groups and the
non-GAS pyoderma cases had no known history of
streptococcal infections, and ASO titres were <300 IU.
This suggested no recent GAS infection in these indi-
viduals. Furthermore, urinalysis of the control 1
showed no proteinuria, protein-creatinine ratio <0.2,
and absence RBCs or pus cells suggesting no subclin-
ical PSGN or CKD in this control group. Figure 1A
shows optical density values for SIC and DRS anti-
bodies, median and quartiles for control 1 and PSGN
cases. The mean values for PSGN are significantly
higher than those of the control (p < 0.05, >0.01;
Figure 1 legend). The calculated cutoff values (mean +
2× standard deviation of the corresponding control)
which are used to determine seroprevalence, are shown
in Figure 1A and C (dotted lines).
The low recovery rates of SIC- and DRS-positive types
(emm1 and emm12) among the pyoderma cases in the
2 years (4.7%, see above) may simply be a reflection of
low prevalence of these types circulating in the KEM
hospital catchment-community. Since SIC and DRS anti-
bodies are persistent [7,8], we would expect rates of
Table 1 Types and subtypes recovered in the two years
of study period
Year 1 Year 2
emm types Recovered from
number of patients
emm types Recovered from
number of patients
emm63.3 3 emm78.3 5
emm82.1 3 emm116.1 3
st9505 3 emm122 5
emm42.3 3 emm 25.2 3
emm22 3 emm 53* 5
emm49.4 4 emm 97.1 2
emm15* 2 emm 227.1 4
emm106 2 emm85.0 5
emm12# 3 emm66* 3
emm53.9 2 emm11.8 3
emm73 2 emm8.1 3
emm86.2 4 emm1*# 3
emm119.2 2 emm106 3
st11014 2 emm58.8 3
st854 2 emm56 1
emm 109.1 2 emm15* 1
emm53* 2 emm49 2
emm15.1 1 emm 112 3
emm60.3 1 emm 4 4
emm66* 1 emm 100 3
emm73.1 1 emm 105 1
emm9 1 emm 111 1
st1731.3 1 emm 102 1
stKNB6 1 emm108 1
emm1*# 1 emm77 1
emm3 1 emm113 2








The strains indicated by # represent SIC or DRS positive types. Types indicated
by asterisks were recovered in both years.
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with the low abundance of these types. In accordance
with this, we observed that 4-6% of the control 1 (also in
control 2 and non-GAS pyoderma; see later) was sero-
positive to SIC, DRS or both (Figures 1B). By contrast,
antibody seroprevalence rates (proportion greater than
mean + 2SD of control 1) in the PSGN patients weresignificantly high; 24% and 36% for SIC and DRS re-
spectively (Figure 1B; correspondingly p = 0.0279; p =
0.0297). Odds ratio (OR) for SIC and DRS antibody
positivity are 7.56 (95% CI 0.84, 68.46; p = 0.07) and
13.5 (95% CI 1.56, 117.14; p = 0.0182) respectively. Our
results in Mumbai population, which is highly endemic
for streptococcal diseases, are concordant with earlier
observations from the Australian Indigenous popula-
tion and Swedish pediatric cases [8,10], and thereby
provide further support to the observation of positive
association between seroprevalence of these antibodies
and PSGN.
We then extended seroprevalence study to GAS pyo-
derma cases and compared to age matched control 2
and non-GAS pyoderma cases (Figure 1C and D). It is
interesting that mean values for control group 2 and
non-GAS pyoderma are not significantly different with
each other or with control 1 (see Figure 1 legend), des-
pite the differences in mean age of the two healthy con-
trol groups. Together, the data for the two control
groups and the non-GAS pyoderma cohort establish
base-level seroprevalence rate of <5% for SIC or DRS
antibodies in this population (Figure 1B and D); and this
rate is in agreement with the recovery rates of SIC- or
DRS-positive emm types in the community (Table 1).
Unexpectedly as shown in Figure 1D, 58 (38.7%) of
GAS pyoderma patients are anti-SIC positive and 56
(37.3%) are anti-DRS positive. These proportions are sig-
nificantly higher (p <0.0001 for each) than for the corre-
sponding control group (control 2). The OR for SIC is
15.13 (95%CI 3.54, 64.64; p =0.0002) and for DRS is 9.33
(95%CI 2.77, 31.40; p =0.0003).
Interestingly, the proportion of the samples reacting to
both SIC and DRS antigens was found to be 28.66% in
the pyoderma cases. This is significantly higher than in
the control group 2 (p = 0.0051; Chi square). The fact
that some patients exhibit seroreaction to one or the
other antigen, suggests that double seropositivity is not
due to possible cross-reactions of the antibodies with
the antigens. Moreover, mature SIC and DRS proteins
have only limited homology; mostly confined to the
proline-rich region [5]. To confirm the true nature of
the double seropositivity, we carried out competitive
ELISAs on a) 6 sera showing reactions to both antigens,
b) 4 sera showing reactions to SIC only and c) 4 sera
showing reactions DRS only. While all the 8 sera show-
ing reactions only to SIC or DRS can be competed out
by pre-incubating the sera with homologous but not
heterologous antigen, the 6 sera reacting to both SIC
and DRS required both the antigens for full competition.
Results with representative sera for each category are
shown in Figure 2. These findings confirm that the sam-
ples with double seropositivity are not artifacts, but rep-
resent true results.
Figure 1 Seroprevalence for SIC and DRS antibodies in PSGN, pyoderma and control groups. Recombinant SIC and DRS proteins with a
thioredoxin tag were used as the streptococcal antigens for ELISA. Background optical density (OD450) readings to thioredoxin were subtracted
from all ODs. OD values for control 1 and PSGN cases (n = 25 each) are shown in panel A and for control 2 (n = 50), GAS pyoderma (n = 150) and
non-GAS pyoderma (n = 50) cases in panel C. The box-whisker plots show median (cross bar in the box), quartiles, and range. The mean OD
values for control 1 are 0.081 and 0.042 for SIC and DRS respectively; and those for control 2 are 0.12 and 0.076 respectively. These means and
those for non-GAS pyoderma cases (0.14 and 0.09 for SIC and DRS respectively) are not significantly different. The means for PSGN and GAS pyoderma
cohorts are significantly higher than their controls for both SIC and DRS (p < 0.05, >0.01 for PSGN; and p < 0.0001 for GAS pyoderma). The calculated
cutoff values (mean + 2x Standard deviation for the corresponding control) is shown as dotted line across. Samples scoring equal to or above the cutoff
values were scored as positive. Panels B and D show per cent seropositive samples for SIC antibodies (black bars) or DRS antibodies (shaded bars) in
each group and compared with respective controls. Lines with asterisks indicate statistically significant differences (** = 0.05≤ p > 0.0001; *** = p≤ 0.0001)
between the means in 1A and 1C, and between proportion of seropositives in 1B and 1D. Lack of such lines means there is no significant differences
between groups (eg; control 2 and non-GAS pyoderma groups in 1C and 1D).
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pyoderma cases, like in the control group 2, is signifi-
cantly lower than in GAS pyoderma cases (p < 0.0001 for
SIC and DRS), we believe this phenomenon of high SIC
and DRS antibody seroprevalence is specific to GAS
pyoderma cases.
Discussion
SIC and DRS antibodies are persistent, and overwhelm-
ing evidence show that the distribution of the SIC and
DRS genes is restricted to mainly four emm types
[7,8,19]. The isolation rate of these four types from our
pyoderma cohort is low (<5%), and our previous study
from this region also show that these types are recovered
in low numbers in Mumbai population [15]. Given these
scenarios, this current observation of high seropreva-
lence rates to SIC and DRS antibodies specifically inpatients with GAS pyoderma caused by many circulating
types is indeed startling. Clearly it points out to in-
creased predisposition to GAS pyoderma among the
subjects who are seropositive to SIC or DRS antibodies
owing to past exposure to emm types expressing these
antigens. We attribute this to a possible role of SIC and
DRS antibodies in a mechanism akin to antibody-
dependent enhancement (ADE) of infection by GAS.
While ADE of infection is common occurrences in
viruses, bacteria too could deploy such strategies. For
instance, ADE of infection has been reported in S. pneu-
moniae [20,21]. Cleavage of IgA1 by bacterial IgA1-
protease enhanced adherence of S. pneumoniae to
respiratory epithelial cells. More recently ADE-like
phenomenon was observed in Pseudomonas aeruginosa
wherein increased severity of respiratory infections was
found to be associated with elevated levels of IgG2
Figure 2 Competitive ELISAs. Sera samples positive to SIC only, DRS only or to SIC + DRS were pre-incubated with homologous, heterologous or
both competitor antigens at 0 μg, 10 μg and 50 μg prior to incubation with SIC (Panel A) or DRS (Panel B) coated plates for ELISA.
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phenomenon we observed here is different in an import-
ant way to what is known in other pathogens; only per-
sistent antibodies to SIC or DRS owing to past infection
by GAS strains expressing these antigens seem to confer
ADE on all strains.
The seroprevalence rate is 38.7% for SIC antibodies in
GAS pyoderma cases, and that for DRS antibodies is
37.3% (Figure 1D). Therefore, we would expect approxi-
mately 14% (38.7% of 37.3%) of the patients to show
seropositivity to both the antibodies. However, we ob-
served 28.66% of the cases were positive to both SIC and
DRS antibodies - twice the expected frequency (the
observed-to-expected ratio of ~2). A likely explanation
for this observation is that SIC or DRS antibody medi-
ated ADE predisposes to skin infections by many GAS
strains including the SIC or DRS positive types. The
above observed-to-expected ratio of 2 suggests that the
rate of enhancement of infection due to SIC or DRS
antibodies may be in the vicinity of two.
Further work is warranted, and being planned, to dem-
onstrate the SIC and DRS mediated ADE-like
phenomenon in pharyngeal infections. Also, demonstra-
tion of the ADE of infection in cell culture or in animal
models may provide further support to this
phenomenon. If ADE of GAS infections occur at boththe major tissue sites, it may offer continued stability for
the host-pathogen interaction in evolutionary terms, and
may be important factor in GAS’s success as a human-
specific pathogen. We suggest that the four SIC and
DRS positive types (emm 1, 12, 55 and 57) are “core
types” and the rest “non-core types”. Global distributions
of emm types clearly show, whereas in most regions one
or more of the 4 “core types” are recovered, the distribu-
tions of the “non-core types” vary considerably with
some types predominating in many places and others
are rarely found or not at all [23,24]. This suggests that
it is possible that there are differences in infectivity
among the emm types. Should the differences persist, it
is possible that contributions to the GAS genetic pool by
the low-infective types would be depleted at the expense
of a few expanding types. ADE by the “core” types may
partly correct this imbalance. Such a scenario may offer
a possible novel strategy for efficient control of GAS dis-
eases by targeting future vaccine candidates against the
“core types”. By such intervention, a decrease in overall
GAS infection may be achieved.
In many populations PSGN is an independent risk
factor for CKD [11-14]. We recently showed that
greater proportion of CKD and ESRD patients was
positive to SIC antibody than that of healthy controls
in the Mumbai population. However, no association
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[15]. Taken together our studies show that whereas
both SIC and DRS seropositivity may predispose to
pyoderma through an ADE-like mechanism, and conse-
quently result in increased seroprevalence in the PSGN
patients, only the SIC antibody-positive PSGN patients
have greater predilection to CKD and ESRD. Hence we
suggest regular monitoring of children positive for SIC
antibodies for signs of stage 1 CKD may provide an
opportunity to offer proactive treatments early, so pro-
gression to ESRD may be averted or delayed.
Conclusions
The role of SIC and DRS is not well understood. It is in-
triguing that only four types express these antigens.
They elicit persistent antibody response. Therefore, anti-
body prevalence in a population is cumulative result of
past infections by one of these four “core” types. Intui-
tively, one would expect that the rate of prevalence
would be the same in a given population among various
subjects; namely subjects with pyoderma, non-GAS
pyoderma, PSGN cases or healthy controls. However,
contrary to this expectation we found that the rate of
seroprevalence is high specifically in GAS pyoderma
cases. Since the pyoderma is resultant of diverse GAS
strains not necessarily expressing these antigens, we in-
terpret the results to mean that antibodies to SIC or
DRS predispose subjects to skin infection by GAS. This
is a unique phenomenon of ADE of infection rendered
by a small number of GAS strains on a wide number of
strains. Such a mechanism could have implications to
maintenance of GAS gene pool despite possible inher-
ent variations in infectivity.
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